Alnylam Pharmaceuticals, Inc. (ALNY) Institutional Ownership & Insider Trading

788 institutions reported holding Alnylam Pharmaceuticals, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 344 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

ALNYAlnylam Pharmaceuticals, Inc.Follow ALNY — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 30.0B
P/E TTM: 41.6
Dividend yield: —
52-week: —
Next earnings: 29 Oct, in 5 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

788 institutions held 99.8% of the shares. Across filers that reported both quarters, shares held changed -0.1%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	788	133	-0.1%	292	61	248	63
Mar 26	782	129	+1.0%	293	67	230	126
Dec 25	829	130	-4.8%	263	99	257	91
Sep 25	800	134	+2.9%	252	185	203	32
Jun 25	645	132	+2.1%	232	82	198	47
Mar 25	608	127	+1.1%	211	79	181	51
Dec 24	573	128	-2.5%	209	50	161	55
Sep 24	552	122	+2.8%	195	88	153	54

Alnylam Pharmaceuticals, Inc. — questions

Who owns Alnylam Pharmaceuticals, Inc. stock?: 788 institutions reported Alnylam Pharmaceuticals, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: FMR LLC (11.2%), Capital World Investors (8.3%), BlackRock, Inc. (8.2%).
Are Alnylam Pharmaceuticals, Inc. insiders buying or selling?: 344 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Alnylam Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.